Keryx Biopharma (KERX) Posts Narrower than Expected Q2 Loss of 2c/Share
Get Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q2 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.
For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mobileye (MBLY) misses estimates for Q1 earnings, revenue; shares slip
- Precision Drilling (PDS) Misses Q1 EPS by 46c
- Textron (TXT) Misses Q1 EPS by 2c, misses on revenue; beats on guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!